Delcath Systems (NASDAQ:DCTH) Earns Buy Rating from Analysts at Craig Hallum

Craig Hallum started coverage on shares of Delcath Systems (NASDAQ:DCTH) in a report issued on Friday, MarketBeat.com reports. The firm issued a buy rating and a $18.00 price target on the stock.

Other equities analysts also recently issued research reports about the stock. HC Wainwright raised their price objective on shares of Delcath Systems from $20.00 to $22.00 and gave the stock a buy rating in a report on Wednesday, May 15th. StockNews.com raised Delcath Systems to a sell rating in a report on Wednesday, March 27th. Finally, Stephens initiated coverage on Delcath Systems in a report on Tuesday, May 14th. They set an overweight rating and a $25.00 price target for the company. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of Moderate Buy and a consensus target price of $19.83.

Delcath Systems Price Performance

NASDAQ:DCTH opened at $8.37 on Friday. The company’s 50-day simple moving average is $6.83 and its 200 day simple moving average is $5.21. Delcath Systems has a one year low of $2.25 and a one year high of $9.18. The firm has a market capitalization of $232.60 million, a P/E ratio of -3.16 and a beta of 0.60.

Delcath Systems (NASDAQ:DCTH) last issued its earnings results on Tuesday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.43). The company had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $3.70 million. Delcath Systems had a negative net margin of 1,080.72% and a negative return on equity of 290.07%. On average, equities research analysts expect that Delcath Systems will post -1.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Levin Capital Strategies L.P. raised its position in shares of Delcath Systems by 12.2% during the first quarter. Levin Capital Strategies L.P. now owns 54,969 shares of the company’s stock valued at $262,000 after buying an additional 5,969 shares during the last quarter. BVF Inc. IL grew its stake in Delcath Systems by 23.1% during the first quarter. BVF Inc. IL now owns 1,202,067 shares of the company’s stock valued at $5,734,000 after acquiring an additional 225,918 shares in the last quarter. Vanguard Group Inc. lifted its stake in Delcath Systems by 31.0% in the 1st quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock worth $3,261,000 after purchasing an additional 161,678 shares in the last quarter. Vivo Capital LLC lifted its stake in Delcath Systems by 94.9% in the 1st quarter. Vivo Capital LLC now owns 1,666,746 shares of the company’s stock worth $7,950,000 after purchasing an additional 811,555 shares in the last quarter. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Delcath Systems during the fourth quarter valued at about $962,000. 61.12% of the stock is owned by hedge funds and other institutional investors.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.